Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients

Cancer Letters

Volumn 255, Issue 1, 2007, Pages 71-76

  Ocaña, Alberto ^a,b,c   Rodríguez Barbero, Alicia ^a,b,c   Pericacho, Miguel ^a,b,c   Bellido, Lorena ^a,b,c   Seijas, Raquel ^a,b,c   López, Rafael ^a,b,c   Delgado, Carlota ^a,b,c   de Prado, Diego Soto ^a,b,c   Cruz Hernández, Juan J ^a,b,c   López Novoa, José M ^a,b,c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Anemia; Endoglin; Erythropoietin; Human recombinant erythropoietic agents; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOGLIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE; VASCULOTROPIN;

ADULT; AGED; ANEMIA; ANGIOGENESIS; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; HUMAN; LUNG NON SMALL CELL CANCER; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547741535     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.03.020     Document Type: Article

References (31)

1. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., and Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19 (2001) 2865-2874
2. Demetri G.D., Kris M., Wade J., Degos L., and Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J. Clin. Oncol. 16 (1998) 3412-3425
3. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., and Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J. Clin. Oncol. 15 (1997) 1218-1234
4. Leyland-Jones B., Semiglazov V., Pawlicki M., Pienkowski T., Tjulandin S., Manikhas G., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J. Clin. Oncol. 23 (2005) 5960-5972
5. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
6. Henke M., Mattern D., Pepe M., Bezay C., Weissenberger C., Werner M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J. Clin. Oncol. 24 (2006) 4708-4713
7. Anagnostou A., Lee E.S., Kessimian N., Levinson R., and Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. USA 87 (1990) 5978-5982
8. Anagnostou A., Liu Z., Steiner M., Chin K., Lee E.S., Kessimian N., and Noguchi C.T. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA 91 (1994) 3974-3978
9. Masuda S., Nagao M., Takahata K., Konishi Y., Gallyas F., Tabira Jr. T., et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J. Biol. Chem. 268 (1993) 11208-11216
10. Mioni R., Gottardello F., Bordon P., Montini G., and Foresta C. Evidence for specific binding and stimulatory effects of recombinant human erythropoietin on isolated adult rat Leydig cells. Acta Endocrinol. (Copenh) 127 (1992) 459-465
11. Ogilvie M., Yu X., Nicolas-Metral V., Pulido S.M., Liu C., Ruegg U.T., et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J. Biol. Chem. 275 (2000) 39754-39761
12. Fraser J.K., Tan A.S., Lin F.K., and Berridge M.V. Expression of specific high-affinity binding sites for erythropoietin on rat and mouse megakaryocytes. Exp. Hematol. 17 (1989) 10-16
13. Westenfelder C., and Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 58 (2000) 647-657
14. Selzer E., Wacheck V., Kodym R., Schlagbauer-Wadl H., Schlegel W., Pehamberger H., et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res. 10 (2000) 421-426
15. Acs G., Acs P., Beckwith S.M., Pitts R.L., Clements E., Wong K., et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 61 (2001) 3561-3565
16. Ribatti D., Marzullo A., Nico B., Crivellato E., Ria R., and Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology 42 (2003) 246-250
17. Metcalf D. Peptide factors, haemopoietic grown factors. Lancet 1 (1989) 825-827
18. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 69 Suppl. 3 (2005) 11-16
19. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
20. Gougos A., and Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J. Biol. Chem. 265 (1990) 8361-8364
21. Wong S.H., Hamel L., Chevalier S., and Philip A. Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. Eur. J. Biochem. 267 (2000) 5550-5560
22. Wang J.M., Kumar S., Pye D., van Agthoven A.J., Krupinski J., and Hunter R.D. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer 54 (1993) 363-370
23. Li D.Y., Sorensen L.K., Brooke B.S., Urness L.D., Davis E.C., Taylor D.G., et al. Defective angiogenesis in mice lacking endoglin. Science 284 (1999) 1534-1537
24. Bourdeau A., Dumont D.J., and Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J. Clin. Invest. 104 (1999) 1343-1351
25. Jerkic M., Rodríguez-Barbero A., Prieto M., Toporsian M., Pericacho M., Rivas-Elena J.V., Obreo J., et al. Reduced angiogenic responses in adult endoglin heterozygous mice. Cardiovasc. Research 69 (2006) 845-854
26. Fonsatti E., Del Vecchio L., Altomonte M., Sigalotti L., Nicotra M.R., Coral S., et al. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J. Cell Physiol. 188 (2001) 1-7
27. Duff S.E., Li C., Garland J.M., and Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 17 (2003) 984-992
28. Rosti V., Pedrazzoli P., Ponchio L., Zibera C., Novella A., Lucotti C., et al. Effect of recombinant human erythropoietin on hematopoietic and non-hematopoietic malignant cell growth in vitro. Haematologica 78 (1993) 208-212
29. Westphal G., Niederberger E., Blum C., Wollman Y., Knoch T.A., Rebel W., et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 88 (2002) 150-159
30. Gewirtz D.A., Di X., Walker T.D., and Sawyer S.T. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin. Cancer Res. 12 (2006) 2232-2238
31. Li C., Guo B., Wilson P.B., Stewart A., Byrne G., Bundred N., et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int. J. Cancer 89 (2000) 122-126